Factors associated with non use of adjuvant trastuzumab in older patients with HER2+breast cancer.

被引：0
|
作者：
Luis, Ines Vaz
Lin, Nancy U.
Keating, Nancy Lynn
Barry, William Thomas
Lii, Joyce
Burstein, Harold J.
Winer, Eric P.
Freedman, Rachel A.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.601
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
601
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Adjuvant and neoadjuvant trastuzumab in combination with vinorelbine for HER2+breast cancer.
    Esfahani, Khashayar
    Ferrario, Cristiano
    Le, Philippe
    Panasci, Lawrence C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] Safety of trastuzumab in women with HER2+breast cancer.
    Nowsheen, Somaira
    Aziz, Khaled
    Park, Jae Yoon
    Villarraga, Hector R.
    Herrmann, Joerg
    Ruddy, Kathryn Jean
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Adjuvant trastuzumab and vinorelbine (TV) for early-stage HER2+breast cancer.
    McLaughlin, Shannon
    Nakajima, Erika
    Isakoff, Steven J.
    Shin, Jennifer
    Moy, Beverly
    Bardia, Aditya
    Kuter, Irene
    Spring, Laura
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2+breast cancer.
    Garrison, L. P., Jr.
    Perez, E. A.
    Dueck, A.
    Lalla, D.
    Paton, V.
    Lubeck, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 306S - 306S
  • [5] TRASTUZUMAB INDUCED CARDIOTOXICITY IN PATIENTS WITH HER2+BREAST CANCER
    Santamaria Elena, Capilla
    Garcia Beatriz, Benitez
    Jose Antonio, Romero Garrido
    Aunon Pilar, Zamora
    Abad Gema, Casado
    del Valle Luis, Gonzalez
    Ambrosio Alicia, Herrero
    [J]. ATENCION FARMACEUTICA, 2013, 15 (04): : 261 - 267
  • [6] Adjuvant trastuzumab and vinorelbine for early-stage HER2+breast cancer
    McLaughlin, Shannon
    Nakajima, Erika
    Bar, Yael
    Hutchinson, Jennifer A. A.
    Shin, Jennifer
    Moy, Beverly
    Isakoff, Steven J. J.
    Bardia, Aditya
    Kuter, Irene
    Spring, Laura M. M.
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [7] Trastuzumab use at relapse after adjuvant trastuzumab therapy in HER2-positive breast cancer.
    Lang, I.
    Bell, R.
    Feng, F.
    Lopez, R. I.
    Jassem, J.
    Semiglazov, V.
    Al-Sakaff, N.
    Carreras, E.
    Chang, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Use of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
    Elkerm, Y.
    Ali, I. M.
    Elsaid, A. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] STAT6 expression and trastuzumab resistance in HER2+breast cancer.
    Cobleigh, Melody A.
    DiScala, Molly
    Najor, Matthew S.
    Yung, Timothy
    Abukhdeir, Abde M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Physician perceptions to use of trastuzumab in HER2+breast cancer in India
    Ramanjinappa, N.
    Agarwal, J.
    Upveja, K. H.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S1437 - S1437
12345